Drug Shortage Report for MILRINONE LACTATE INJECTION, USP

Last updated on 2022-08-04 History
Report ID 166152
Drug Identification Number 02244622
Brand name MILRINONE LACTATE INJECTION, USP
Common or Proper name MILRINONE LACTATE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) MILRINONE
Strength(s) 1MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 10mL
ATC code C01CE
ATC description CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2022-08-01
Estimated end date 2022-09-01
Actual end date
Shortage status Actual shortage
Updated date 2022-08-04
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be facing a supply interruption on our Milrinone Lactate Injection 1 mg/mL SD Vial 10 mL effective August 1, 2022 until September 1, 2022.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v2 2022-08-04 French Compare
v1 2022-08-04 English Compare

Showing 1 to 2 of 2